CBX 1
Alternative Names: CBX-1Latest Information Update: 28 Feb 2022
At a glance
- Originator Vaxeal Holding
- Class Cancer vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Head and neck cancer; Lung cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Switzerland (Parenteral)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Lung-cancer in Switzerland (Parenteral)
- 17 Jan 2018 Vaxeal Holding and Commissariat à l’Energie Atomique enter into license agreements for the protection of T-cell epitopes of cyclin B1 (Vaxeal Holding website, January 2018)